Abstract Presentation Highlights from the 2024 EAACI Annual Meeting
Résumé
Many oral abstracts, posters and case reports were presented at The European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting which was held in June 2024 in Valencia, Spain. We have selected the following 13 articles due to their relevance to Canadian allergy and immunology clinical practice and research.
Références
Metz, M. Long-term efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria in the Phase 3 REMIX-1 and REMIX-2 studies. Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, Valencia, Spain.
Maurer, M. Dupilumab improves urticaria activity, health-related quality of life, and disease perception and severity in patients with CSU: results from the LIBERTY-CSU CUPID A study. Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, Valencia, Spain.
Galimova, A. Efficacy and safety of therapy with omalizumab in children with chronic spontaneous urticaria. Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, Valencia, Spain.
Lugogo, NL. Patients with moderate-to-severe asthma treated with dupilumab are more likely to meet clinical remission criteria: results from the VESTIGE trial presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, Valencia, Spain.
Soliman, M. Dupilumab reduces FeNO levels and exacerbations and improves asthma control with inhaled corticosteroid withdrawal: a phase 2 study. Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, Valencia, Spain.
Greenhawt M, Sindher SB, Wang J, et al. Phase 3 trial of epicutaneous immunotherapy in toddlers with peanut allergy. N Engl J Med. 2023;388:1755-66.
International consensus guidelines for the diagnosis and management of food protein-induced enterocolitis syndrome: Executive summary-workgroup report of the adverse reactions to foods Committee, American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2017 Apr;139(4):1111-26.e4.
Chehade M, Dellon ES, Spergel JM, et al. Dupilumab for eosinophilic esophagitis in patients 1 to 11 years of age. N Engl J Med. 2024 Jun 27;390(24):2239-51.
Riedl MA. Hereditary angioedema during pregnancy: considerations in management. Immunol Allergy Clin North Am. 2023 Feb;43(1):145-57.
The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update, Allergy. 2022 Jul;77(7):1961-90.
Atkinson A, Poliquin V, Elwood C. Penicillin allergy de-labelling in pregnancy CMAJ. 2023 Mar 27;195(12):E452-53.
Blumenthal KG, Shenoy E. Penicillin allergy in pregnancy. JAMA. 2020 Mar 24;323(12):1216.
